BioSniper
Phase 2 Startpositive

Phase 2 Start: A Randomized, Double-Blind, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo fo

July 1, 2026
Company
GH Research PLC (GHRS)
Indication
Crohn Disease (CD)

Other upcoming events for GHRS

Phase 2 StartPhase 2 Start: A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's D
Jul 1, 2026
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label Intrathecal Administration of TSHA-105 to Determine the Safety and Efficacy i
Aug 1, 2026
Phase 2 StartPhase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled
Sep 1, 2026
Phase 2 StartPhase 2 Start: MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Eithe
Oct 3, 2026
Phase 2 StartPhase 2 Start: A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Transl
Oct 14, 2026

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
GHRS OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle